Modality
ADC
MOA
BiTE
Target
Aβ
Pathway
Sphingolipid
NB
Development Pipeline
Preclinical
Jul 2018
→ Jan 2031
PreclinicalCurrent
NCT04877888
568 pts·NB
2018-07→2031-01·Terminated
568 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-01-104.8y awayInterim· NB
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Termina…
Catalysts
Interim
2031-01-10 · 4.8y away
NB
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04877888 | Preclinical | NB | Terminated | 568 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ |